This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Xylem (XYL) Displays Bright Prospects Despite Headwinds
by Zacks Equity Research
Xylem (XYL) is likely to benefit from new products, innovation and focus on operational execution in the quarters ahead. However, soft end markets amid the coronavirus pandemic are concerning.
Xylem (XYL) Declines 19% YTD: What's Affecting the Stock?
by Zacks Equity Research
Xylem (XYL), with shares down 19% so far in 2020, faces risks from difficult end-market conditions due to the pandemic, forex woes and cost inflation. Q2 organic sales are likely to fall 20-30% y/y.
Why Is Xylem (XYL) Up 11.1% Since Last Earnings Report?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher's Stock Offering Proceeds to Fund Corporate Needs
by Zacks Equity Research
Danaher (DHR) completes the offering of common and convertible preferred shares. It intends on using the funds raised to pay for its corporate needs.
Xylem (XYL) Q1 Earnings Lag Estimates, Organic View Weak
by Zacks Equity Research
Xylem's (XYL) Q1 results reflect the adverse impacts of the coronavirus outbreak, a fall in margins and forex woes. Organic sales in Q2 are expected to reflect the uncertainties as well.
Xylem (XYL) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of -37.84% and -1.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) Q1 results are expected to reflect the adverse impacts of the uncertainties caused by the coronavirus outbreak. But healthy balance sheet and cost actions might have aided.
Analysts Estimate Xylem (XYL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How are Industrial Product Stocks Placed for Q1 Earnings?
by Payal Jalan
The coronavirus outbreak mars earnings and revenue prospects for many companies under the Industrial Products sector. Collective results for the first quarter of 2020 might be lackluster.
Drab Near-Term Prospects for Industrial Manufacturing Stocks
by Avisekh Bhattacharjee
The Manufacturing - General Industrial industry is facing coronavirus-related issues, job losses & other problems. Technological advancement in manufacturing processes will likely be a growth driver.
NPO vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NPO vs. XYL: Which Stock Is the Better Value Option?
Flowserve (FLS) Withdraws Annual View on Coronavirus Concerns
by Zacks Equity Research
Flowserve (FLS) withdraws guidance for 2020, owing to uncertainties in the end-markets on the impacts of the coronavirus outbreak.
Xylem (XYL) Withdraws Guidance Based on Coronavirus Concerns
by Zacks Equity Research
Xylem (XYL) withdraws guidance for the first quarter and 2020, owing to the coronavirus outbreak.
NPO vs. XYL: Which Stock Is the Better Value Option?
by Zacks Equity Research
NPO vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Declines 18% YTD: What's Hurting the Stock?
by Zacks Equity Research
Xylem (XYL), with an 18% decline in shares so far in 2020, faces headwinds from the coronavirus outbreak, softness in commercial and industrial markets, and soft orders.
Xylem (XYL) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Reasons Why You Should Avoid IDEX (IEX) Stock for Now
by Zacks Equity Research
IDEX (IEX) is exposed to challenging end markets, unfavorable movements in foreign currencies, and the impacts of variable compensation, tax rate and growth investments.
Here's Why Investors Should Ignore Xylem (XYL) Stock for Now
by Zacks Equity Research
Xylem (XYL) is exposed to challenging end markets, issues related to Coronavirus, soft orders and others. The headwinds are expected to adversely impact its results in the first half of 2020.
Xylem (XYL) Q4 Earnings Estimates Meet, Dividend Rate Rises
by Zacks Equity Research
Xylem's (XYL) Q4 earnings came in line but the same improves year over year on lower interest expenses. The company declares an 8% raise in quarterly dividend rate.
Xylem (XYL) Matches Q4 Earnings Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 0.00% and -0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Xylem's (XYL) Q4 is likely to have gained from the emerging markets business, productivity moves and positive pricing. But soft volumes, end-market weakness and lower margin mix might have ailed.
Xylem (XYL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Softness in End Markets and Forex Woes to Hurt Xylem (XYL)
by Zacks Equity Research
Xylem's (XYL) 2019 performance will likely suffer from softness in certain end markets and unfavorable movements in foreign currencies. High costs and huge debts are other concerns.
Dull Near-Term Prospects for Industrial Manufacturing Stocks
by Zacks Equity Research
The Manufacturing - General Industrial industry is facing material cost inflation issues. In the long term, technological advancement in manufacturing processes is likely to be a major growth driver.
Xylem (XYL) Meets Q3 Earnings Estimates, Lowers '19 View
by Zacks Equity Research
Xylem's (XYL) third-quarter 2019 earnings meet estimates but rise year over year on solid organic sales and improved margins. The company lowers 2019 earnings projection.